Hoofddorp, the Netherlands, 3June 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mrs. Rosanna Squitti and Mr. Giovanni Ferrario from its board of directors. Mr. Ferrario resigned for personal reasons and Mrs. Squitti left the corporate body for continuing to serve as Chief Scientific Officer of the Company. The Board furthermore elected Mrs. Giovanna Puppo as new Chairman, substituting Mr. Francesco Mario Patrocollo who will newly assume the role of vice Chairman.

Continue reading →






Hoofddorp, the Netherlands, 25 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the entry into the final stage of negotiations with an institutional investor, following to a letter of intent (LOI) binding in terms, for a convertible bond facility arrangement over the next 24 months. The closing is expected to be within the first half of April 2021.

Under the terms of the LOI and subject to closing, the investor will commit for up to EUR 10 million over the next 24 months.

Continue reading →

This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed on https://www.igeapharma.nl/category/press-releases.

Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced important changes in its board of directors. As announced today by separate press release, new persons were bindingly nominated for election as non-executive directors in the board of IGEA at the upcoming extraordinary general meeting of 28 April 2021.

Continue reading →

Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the convening of an extraordinary general meeting (the “EGM”) for Wednesday, 28 April 2021. The EGM will resolve on matters regarding the business combination with Blue Sky Natural Resources LTD (“BSNR”) as further indicated below (and as previously disclosed by IGEA on 8 August 2020 and 15 February 2021) and on the appointment of newly proposed non-executive directors.

Continue reading →